Page view：
产品描述
EAL® is a multi-target cellular immunotherapy product with more than a decade of track record of clinical application in the treatment of cancer. It is a preparation of activated and expanded T cells originally taken from a patient’s autologous peripheral blood and cultured using our patented methods(Patent number: ZL200710102854.0). The main active component of the product is CD3+ CD8+ cytotoxic T cells.The efficacy of activated autologous lymphocytes (AAL) therapy (of which EAL® is an example) in the prevention of postsurgical recurrence of liver cancer has been seen in overseas clinical trials. Separately, the safety and efficacy of EAL® produced using our patented methods in the treatment of tumours have been reported in three SCI academic journal articles.